Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Candel Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $49.13M, up 131.3% year over year. For fiscal 2025 it was $30.50M, up 57.9% from the year before. The highest annual figure on record is $30.50M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.50M | +57.9% |
| FY2024 | Dec 31, 2024 | $19.31M | -21.2% |
| FY2023 | Dec 31, 2023 | $24.51M | +17.9% |
| FY2022 | Dec 31, 2022 | $20.79M | +37.0% |
| FY2021 | Dec 31, 2021 | $15.18M | +73.4% |
| FY2020 | Dec 31, 2020 | $8.75M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.80M | +183.2% |
| Q1 FY2026 | Mar 31, 2026 | $9.84M | +145.0% |
| Q4 FY2025 | Dec 31, 2025 | $11.03M | +128.9% |
| Q3 FY2025 | Sep 30, 2025 | $8.46M | +56.2% |
| Q2 FY2025 | Jun 30, 2025 | $6.99M | +40.4% |
| Q1 FY2025 | Mar 31, 2025 | $4.02M | -2.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.82M | -33.6% |
| Q3 FY2024 | Sep 30, 2024 | $5.42M | -7.3% |
| Q2 FY2024 | Jun 30, 2024 | $4.98M | -16.1% |
| Q1 FY2024 | Mar 31, 2024 | $4.10M | -25.0% |
| Q4 FY2023 | Dec 31, 2023 | $7.26M | +46.0% |
| Q3 FY2023 | Sep 30, 2023 | $5.85M | +8.7% |
| Q2 FY2023 | Jun 30, 2023 | $5.93M | +18.2% |
| Q1 FY2023 | Mar 31, 2023 | $5.47M | +1.0% |
| Q4 FY2022 | Dec 31, 2022 | $4.97M | +29.0% |
| Q3 FY2022 | Sep 30, 2022 | $5.38M | +2.1% |
| Q2 FY2022 | Jun 30, 2022 | $5.02M | +52.6% |
| Q1 FY2022 | Mar 31, 2022 | $5.42M | +96.8% |
| Q4 FY2021 | Dec 31, 2021 | $3.85M | +9.1% |
| Q3 FY2021 | Sep 30, 2021 | $5.27M | +190.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.29M | +83.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.75M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.53M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.81M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.80M | – |
See a number that looks wrong?